Clinical application of T-cell therapy in bladder cancer:methods,advantages and limitations
10.3969/j.issn.1009-8291.2025.10.013
- VernacularTitle:T细胞疗法在膀胱癌治疗中的临床应用:方法、优势与局限性
- Author:
Xuyang HAO
1
;
Xiangyu WU
1
;
Xin YANG
1
;
Hongqian GUO
1
;
Rong YANG
1
Author Information
1. 南京大学医学院附属鼓楼医院泌尿外科,江苏南京 210008
- Publication Type:Journal Article
- Keywords:
bladder cancer;
adoptive cell immunotherapy;
T-cell therapy;
tumor infiltrating lymphocyte therapy;
T cell receptor engineered T-cell therapy;
chimeric antigen receptor T-cell therapy
- From:
Journal of Modern Urology
2025;30(10):889-894
- CountryChina
- Language:Chinese
-
Abstract:
T-cell therapy,as an emerging strategy for bladder cancer treatment,primarily includes tumor-infiltrating lymphocyte(TIL)therapy,T cell receptor-engineered T-cell(TCR-T)therapy,and chimeric antigen receptor T-cell(CAR-T)therapy.TIL therapy involves extracting,expanding,and reinfusing tumor-infiltrating T cells,aiming to promote tumor regression,which has achieved initial progress in the field of bladder cancer.TCR-T therapy involves genetically modifying T cells to specifically recognize tumor antigens presented by MHC,with clinical trials targeting NY-ESO-1 and other targets progressing in an orderly manner.CAR-T therapy utilizes artificially designed CAR molecules to target bladder cancer-highly expressed antigens such as prostate-specific membrane antigen(PSMA)and human epidermal growth factor receptor 2(HER2),with multiple studies confirming its potent cytotoxic effects.This article systematically summarizes the existing research,advantages and limitations of T-cell therapy in bladder cancer,so as to provide reference for exploring new options for the next-generation immunotherapy strategies of bladder cancer.
